| Bioactivity | NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosomes through an enzyme-instructed self-assembly (EISA) mechanism catalyzed by cathepsin B. This process triggers lysosomal swelling, membrane permeabilization (LMP), and membrane disruption, ultimately leading to cancer cell apoptosis via a non-classical caspase-independent pathway. NDI-Lyso exhibits significant selective anticancer activity in various cancer cell lines and drug-resistant cancer cells (IC50 ~10 μM) while showing low toxicity to normal cells (IC50 > 60 μM)[1]. |
| CAS | 2999646-19-2 |
| Sequence | {Hexyl-NDI-βAla}-Phe-Phe-Arg-Arg-Arg-Arg-Lys |
| Shortening | {Hexyl-NDI-βAla}-FFRRRRK |
| Formula | C71H100N22O13 |
| Molar Mass | 1469.69 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jana B, et al. Intra-Lysosomal Peptide Assembly for the High Selectivity Index against Cancer. J Am Chem Soc. 2023 Aug 23;145(33):18414-18431. |
NDI-Lyso
CAS: 2999646-19-2 F: C71H100N22O13 W: 1469.69
NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosome
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.